M. R. Garcia Campelo - CHUAC, University Hospital A Coruña

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 50 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON

E. Felip, C.A. Shu, A. Aguilar, K-J. Tang,M.R. García Campelo, K-Y. Lee, A. Delmonte, J. Sabari, N. Girard, A.S. Mansfield, K. Park, C. Zhou,

ESMO Open (2024)

引用0浏览0引用

5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study

M.R. García Campelo,B.C. Cho, N. Girard, S. Lu, H. Yoshioka, J-S. Lee,S-H. Lee, B. Liu, M.A.N. Sendur, B. Besse, A. Spira, E. Felip,

ESMO Open (2024)

引用0浏览0引用

201P Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: An international multicentric analysis

M.I. Gomez-Randulfe Rodriguez, C. Escriu, S. Mohammed, R. Shah, J.D. Benitez Fuentes, S. Cox, F. Monaca, E. Bria, S. Silva Diaz,M.R. García Campelo, B. Crook, T. Talbot,

ESMO Open (2024)

引用0浏览0引用

38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L

A. Delmonte,M-J. Ahn, S. Ghosh, M.J. Hochmair,T-Y. Yang,J.C-H. Yang,J-Y. Han, K.H. Holmskov,Y. Wu, Y. Wan, M. Lin, J. Kretz,

ESMO Open (2024)

引用0浏览0引用

209P Small cell lung cancer in never smokers: A descriptive analysis

A. Ruano-Ravina, C. Candal Pedreira,V. Calvo de Juan,M. Cobo Dols,J.M. Trigo Perez,D. Rodriguez Abreu, A. Estival Gonzalez, E. Carcereny,M. Cucurull Salamero, R. López Castro,M.R. García Campelo, P. Cordeiro González,

ESMO Open (2024)

引用0浏览0引用

PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L

D Ross Camidge,H. Ryun Kim,M.J. Ahn,James CH. Yang,J.-Y. Han,M.J. Hochmair, K.H. Lee,A. Delmonte,M.R. Garcia Campelo,D.-W. Kim,F. Griesinger,E. Felip,

Journal of Thoracic Oncologyno. 3 (2023): e27-e27

引用0浏览0引用

Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L

D. Ross Camidge,H. Ryun Kim,M. J. Ahn,James Ch. Yang,J. -Y. Han,M. J. Hochmair, K. H. Lee,A. Delmonte,M. R. Garcia Campelo,D. -W. Kim,F. Griesinger,E. Felip,

JOURNAL OF THORACIC ONCOLOGYno. 3 (2023): E27-E27

引用0浏览0引用

1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

M.R. Garcia Campelo,M. Domine Gomez,J. De Castro Carpeno,A.L. Moreno Vega,S. Ponce Aix, E. Arriola,E. Carcereny Costa,M. Majem Tarruella, G. Huidobro Vence,E. Esteban Gonzalez,J. Fuentes Pradera,A.L.O. Ortega Granados,

Annals of Oncology (2022): S1246-S1247

引用3浏览0引用

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

M-J. Ahn,S-W. Kim,E. Carcereny Costa,L.M. Rodríguez,J. Oliveira,M.A. Insa Molla, M. Majem,L. Costa,W-C. Su, K.H. Lee,J.C-H. Yang, D.R. Spigel,

Annals of Oncology (2022): S1423-S1423

引用0浏览0引用

Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC)

F. Griesinger, D. R. Camidge,H. R. Kim, M. -J Ahn,J. C. Yang,J. -Y Han, M. Hochmair, K. H. Lee, A. Delmonte,M. R. Garcia Campelo,D. -W Kim, E. Felip,

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn